Accurate identification at an early stage of infection is critical for effective care of any infectious disease. The “coronavirus disease 2019 (COVID-19)” outbreak, caused by the virus “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)”, corresponds to the current and global pandemic, characterized by several developing variants, many of which are classified as variants of concern (VOCs) by the “World Health Organization (WHO, Geneva, Switzerland)”. The primary diagnosis of infection is made using either the molecular technique of RT-PCR, which detects parts of the viral genome’s RNA, or immunodiagnostic procedures, which identify viral proteins or antibodies generated by the host. As the demand for the RT-PCR test grew fast, several inexperienced producers joined the market with innovative kits, and an increasing number of laboratories joined the diagnostic field, rendering the test results increasingly prone to mistakes. It is difficult to determine how the outcomes of one unnoticed result could influence decisions about patient quarantine and social isolation, particularly when the patients themselves are health care providers. The development of point-of-care testing helps in the rapid in-field diagnosis of the disease, and such testing can also be used as a bedside monitor for mapping the progression of the disease in critical patients. In this review, we have provided the readers with available molecular diagnostic techniques and their pitfalls in detecting emerging VOCs of SARS-CoV-2, and lastly, we have discussed AI-ML- and nanotechnology-based smart diagnostic techniques for SARS-CoV-2 detection.
1 March 2021 in European Journal of Medicinal Chemistry
Cervical cancer is one of the most prevalent forms of cancer occurring across the world and it has been observed that about 99.7% of cervical cancer cases occur due to infections with the Human papillomavirus (HPV). Over prolonged durations, cervical cancer can lead to complications such as vaginal bleeding, itching, and in more severe instances, even the fatality of the individual. Cervical cancer is an essential cause of death at an early age as it affects young women higher than other populations. The most frequent drugs used in its treatment include antiangiogenic drugs. This review summarizes analytical techniques used for the quantification of anti-angiogenic agents- Bevacizumab, Sunitinib, Pazopanib, Brivanib, and Imatinib. Furthermore, an in-depth description of numerous techniques including NIR (1), HPLC (10), LC-MS (28), and HPTLC (1) approaches used to determine and quantify these agents have been provided in this review. Based on the matrix utilized, the following details were discussed: analytical conditions, detection limits, and solvent used in sample preparation. Our review holds significant importance within the scientific community, offering valuable insights into commonly employed measurement techniques and the latest advancements in these approaches.
1 January 2026 in Journal of Analytical Methods in Chemistry
Exhaled breath analysis (EBA) has evolved as a noninvasive diagnostic technique with enormous promise in healthcare. The development in this area is based on the concept that the breathalyzers employed to measure the alcohol concentration in the blood can be utilized to evaluate health by analyzing the intricate chemical makeup of exhaled breath, which includes various volatile organic compounds (VOCs). Breath analysis could be the driver of personalized medicine and used in early disease identification as it involves the detection of a variety of disease‐specific biomarkers. In diagnostics, EBA offers a noninvasive procedure of illness identification and monitoring. This approach allows for early detection, personalized treatment options, and therapeutic monitoring by detecting disease‐specific VOC biomarkers such as acetone in diabetes and ethane in lipid peroxidation. Also, EBA can measure environmental exposures such as air pollution or occupational dangers. By identifying VOCs from various sources, researchers can measure exposure levels and assess related health hazards. Advances in the analytical methods, including mass spectrometry, gas chromatography, and sensor arrays made it possible to quantify and identify VOCs in exhaled air with high sensitivity and precision. This review focuses on the biomarkers present in breath and their role in identifying diseases. It covers the essential compounds found in breath and their biochemical processes. Furthermore, an in‐depth examination of different methods for identifying biomarkers in breath and the factors influencing VOC concentrations, including age, storage conditions, external sources, and the difference between dead space air and alveolar air, has been discussed.
The receptor tyrosine kinase c-Met was discovered in 1980s as translocated promoter region (TPR)-Met fusion oncogene and has high affinity to its naturally occurring ligand, hepatocyte growth factor (HGF). Binding of HGF to its receptor c-Met, initiates a wide range of cellular signaling, including those involved in proliferation, motility, migration and invasion. Importantly,